Pedmark
Payments companies reported to CMS as associated with Pedmark. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Pedmark, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Pedmark
These are the largest totals companies reported as associated with Pedmark. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ralph Boccia | Bethesda, MD | Hematology & Oncology | $90,389.01 |
| Scott Penney | San Antonio, TX | Pediatric Hematology-Oncology | $52,499.14 |
| Noah Federman | Los Angeles, CA | Pediatric Hematology-Oncology | $45,105.52 |
| Ryuma Tanaka | Columbus, OH | Pediatric Hematology-Oncology | $12,996.80 |
| Leslie Worona | New York, NY | Family | $6,974.25 |
| Amanda French | El Paso, TX | Nurse Practitioner | $2,749.90 |
| Dana Obzut | Tampa, FL | Pediatric Hematology-Oncology | $2,276.00 |
| Wajahat Khan | Grosse Pointe Woods, MI | Medical Oncology | $2,200.00 |
| Sajeel Chowdhary | Tampa, FL | Neurology (Psychiatry & Neurology) | $1,903.50 |
| Ajaz Khan | Zion, IL | Hematology & Oncology | $1,674.43 |
Prescribed Pedmark?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.